GA-AGCO
16.10.2018 14:02:06 CEST | Business Wire | Press release
AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and solutions, today announces that Martin Richenhagen, Chairman, President and Chief Executive Officer of AGCO Corporation, has been named a Chevalier (Knight) of the Légion d'Honneur (Legion of Honor) by the government of France. This high-ranking honorary decoration was bestowed during a recent ceremony held at AGCO’s global headquarters in Duluth, in the presence of the French Consul General in Atlanta, Louis de Corail.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005270/en/
The Legion of Honor, established by Napoléon Bonaparte in 1802, is the highest distinction conferred by the government of France. It is awarded to recognize those people and organizations that have made outstanding contributions to France in a variety of fields.
AGCO began operations in France, when the group became the parent company of the Massey Ferguson brand in 1994, taking ownership of the Beauvais Massey Ferguson plant. Opened in 1960, the Beauvais AGCO site remains today the Global Centre of Excellence for Massey Ferguson engineering and manufacturing, as well as the first private employer of the whole Picardie region. Summing up its operations from Beauvais, Ennery and Courcouronnes, as well as its joint ventures GIMA and AGCO Finance, AGCO has approximately 2,500 employees in the country. As continental Europe's second largest economy, and one of the largest markets for farm machinery, France represents a strategically important market for AGCO. In France, AGCO actively drives business activities centered on the design, manufacture and distribution of farm machinery, strongly contributing to the French economy.
This decoration is in recognition, under Martin Richenhagen’s leadership, of AGCO’s contributions to the development of France and France-USA relations.
Conferring the Legion of Honor on behalf of French President Emmanuel Macron, Dr. Monique Seefried, Chevalier in the Order of the Legion of Honor said: "I would like to thank Martin Richenhagen for his personal commitment and trust in our country's economy. I pay tribute, through him, to the strength of AGCO Corporation, a global leader in the design, manufacture and distribution of agricultural machinery and solutions, and to its willingness to expand and develop in Europe, and especially in France where AGCO’s French-made tractors are admired and respected. Tractors embody our past and our future, linking our ancient human roots in agriculture to the technological progress of the 20th century. Tractors bring us back to the land, to the oldest profession of farming while heralding the power of machinery and industry.”
Martin Richenhagen commented: “It is indeed an honor and privilege to receive this prestigious decoration from the French Government. I am delighted and proud to have our French operations receive such high recognition. In developing our business in Europe, a region which for AGCO is first in revenue contribution, France is a strategic market of great importance. During the past six years, we have invested more than 300 million euros in our Beauvais and Ennery operations, creating close to 300 new jobs to support our ambition for growth. This would not have been possible without the outstanding commitment of our 2,500 employees and this recognition is also theirs. We truly consider France as a business friendly environment supported by an entrepreneurial policy led by President Emmanuel Macron. We hope to make ever-more progress in our development, to contribute to further growing the relationship between France and the USA.”
Martin Richenhagen was selected by the Board of Directors in March 2004 as President and Chief Executive Officer of AGCO Corporation. He was appointed to Chairman of the Board on August 15, 2006.
Under his leadership, AGCO’s operations in France has been through outstanding transformation and success including the following key milestones:
- 2013 – The Beauvais 2 Cab facility and International Sales Training Centre for the Massey Ferguson brand opens. This 15.5 million euros investment created 100 new jobs.
- 2016 – The Beauvais site receives two coveted awards: Best Foreign Exporter 2016 as the first producer and exporter of farm machinery in France; and Factory of Year 2016 for its lean manufacturing implementation and number one in quality approach.
- 2017 – At Ennery, AGCO’s European Parts Warehouse and Distribution Centre moves from 30,000 m² to 100,000 m² and will create 62 jobs by the end of 2018 after a 2.1 million euros investment.
- 2018 – Only five years after the opening of its new cab facility, on August 28th , AGCO launches the operations of its new Logistic Centre in Beauvais after investing another 11 million euros and creating 103 new jobs.
About AGCO
AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural solutions and supports more productive farming through its full line of equipment and related services. AGCO products are sold through five core brands, Challenger®, Fendt®, GSI®, Massey Ferguson® and Valtra®, supported by Fuse® precision technologies and farm optimization services. Founded in 1990, AGCO is headquartered in Duluth, GA, USA. In 2017, AGCO had net sales of approximately $8.3 billion. For more information, visit http://www.AGCOcorp.com . For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005270/en/
Contact:
AGCO Ulrich Stockheim, +1 770-813-6002 Chief Communications Officer Ulrich.Stockheim@AGCOcorp.com Cell: +49 1732993545 or Xavier Arruego, +33 3 44 11 29 40 Manager, Public Relations AGCO EME Xavier.Arruego@AGCOcorp.com Cell: +33 6 70 65 77 00
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
